Q-omics provides the consensus-scored CACNA2D4 profile across patient tissues and cancer cell-line models. CACNA2D4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CACNA2D4 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, CACNA2D4 RNA expression shows 18,014 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, KIRC, and GBM as cancer lineages where CACNA2D4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CACNA2D4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CACNA2D4 survival associations across molecular data types. CACNA2D4 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CACNA2D4 RNA expression–survival associations across cancer types. High CACNA2D4 expression shows unfavorable associations in OV and LGG, but favorable associations in HNSC, UCEC, SKCM and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CACNA2D4 RNA expression.
This table summarizes CACNA2D4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CACNA2D4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CACNA2D4 shows lower tumor expression in LUSC, THCA, PAAD and UCEC and higher tumor expression in KIRC and CHOL. The KIRC box plot shows higher CACNA2D4 RNA expression in tumor versus normal tissue (log2 FC = +1.082, t-test p < 0.001).
This table shows molecular features associated with CACNA2D4 in patient tissues and cancer cell lines. In patient samples, CACNA2D4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CACNA2D4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
